[Activity Report] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)
date : 11/2/2022
Tags: AMR
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery, for which AMR Alliance Japan (Secretariat: HGPI) is a cooperating member, has released recommendations on “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.”
The recommendation can be found here.
*Available Only in Japanese
■The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery is comprised of The Japanese Society of Chemotherapy, The Japanese Association for Infectious Disease, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society for Bacteriology, The Pharmaceutical Society of Japan, and The Japanese Society of Veterinary Science. It investigates the promotion of infectious disease therapy and drug therapy from a medical perspective.
■AMR Alliance Japan
AMR Alliance Japan AMR was established in November 2018 as a multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of August 2022, its members include MSD K.K., “Kodomo to Iryo” Project, Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, NISSUI Pharmaceutical Co., Ltd., Nippon Becton Dickson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japanese Society of Hospital Pharmacists, The Pharmaceutical Society of Japan; The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.
Top Research & Recommendations Posts
- [Research Report] Energy Conservation and Greenhouse Gas Emissions Reduction in Healthcare Facilities: Case Studies from New Construction and Facility Renewal (March 16, 2026)
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Public Comment Submission] “The 7th Science, Technology and Innovation Basic Plan” (Draft) (February 19, 2026)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Research Report] The 2026 Public Opinion Survey on Healthcare in Japan (February 13, 2026)
- [Policy Recommendations] Dementia Project “The Future of Dementia Policy Surrounding Families and Others Who Care for People with Dementia” (April 27, 2026)
- [Publication Report] Future of the Healthcare System Project “Policy roadmaps for acting early on NCDs” (March, 2026)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] AMR Policy Update #2: WHO’s First Report on Fungal Infection—Bridging the Gap Between Clinical Practice and R&D
Featured Posts
-
2026-05-13
[Registration Open] HGPI Salon 2025-2026 Looking Ahead to the Future of Japan’s Social Security System “Session 5: The Value of Healthcare in Society – Perspectives from the Reiwa Era” (June 29, 2026)
-
2026-05-15
[Registration Open] (Webinar) The 2nd J-PEP Seminar – A New Framework for Providing Information on Clinical Trial Participant Recruitment – Legal Points to Consider from the Perspective of Meaningful Involvement (June 15, 2026)
-
2026-05-18
[Registration Open] Kick-off Panel Discussion “From Japan and Africa, in Discussion with the World: Cultivating Together a Philosophical Dialogue on Health” (June 15, 2026)
-
2026-05-19
[Registration Open] (Webinar) HGPI Special Seminar “Building a Society Where People Live with Blood Disorders: The Future of Blood Disorder Policy as Examined from the Frontlines of Home-Based Care × Lived Experience Research” (June 12, 2026)



